Xiamen Amoytop Biotech (688278.SH) is expected to achieve a net profit of 810 million to 840 million yuan in 2024, a year-on-year increase of 45.83% to 51.23%.

Xiamen Amoytop Biotech (688278.SH) announced that, according to preliminary calculations by the company's finance department, it is expected to achieve a net profit attributable to the owners of the parent company of 8.1 billion yuan to 8.4 billion yuan in the fiscal year 2024. Compared to the same period last year (legally disclosed data), it is expected to increase by 254.55 million yuan to 284.55 million yuan, a year-on-year growth of 45.83% to 51.23%. The company expects to achieve a net profit attributable to the owners of the parent company excluding non-recurring gains and losses of 805 million yuan to 835 million yuan in the fiscal year 2024. Compared to the same period last year (legally disclosed data), it is expected to increase by 225.61 million yuan to 255.61 million yuan, a year-on-year growth of 38.94% to 44.12%. During the reporting period, the company's main business performed well, especially with the continuous advancement of clinical research on hepatitis B cure. The company's product, Pegasbin as a first-line treatment for chronic hepatitis B, has gained further recognition from experts and patients, leading to a significant increase in operating performance year-on-year.